注射用依替巴肽用于高危急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗术的验证性试验
[Translation] A confirmatory trial of eptifibatide for injection for percutaneous coronary intervention in high-risk acute coronary syndrome (ACS) patients
(1)验证注射用依替巴肽用于高危ACS患者经皮冠状动脉介入治疗术的有效性 (2)验证注射用依替巴肽用于高危ACS患者经皮冠状动脉介入治疗术的安全性
[Translation] (1) To verify the effectiveness of eptifibatide for injection in percutaneous coronary intervention in high-risk ACS patients (2) To verify the safety of eptifibatide for injection in percutaneous coronary intervention in high-risk ACS patients
[Translation] Pharmacokinetic-Pharmacodynamic Study of Etifibatide for Injection in Healthy Humans
评估注射用依替巴肽在健康人体的药代动力学和药效动力学特征,获得药效动力学和药代动力学数据,建立PK/PD 模型,为指导临床用药提供依据。
[Translation] To evaluate the pharmacokinetic and pharmacodynamic characteristics of eptifibatide for injection in healthy humans, obtain pharmacodynamic and pharmacokinetic data, and establish a PK/PD model to provide a basis for guiding clinical medication.
100 Clinical Results associated with Hainan Shuangcheng Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Hainan Shuangcheng Pharmaceuticals Co., Ltd.
100 Deals associated with Hainan Shuangcheng Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Hainan Shuangcheng Pharmaceuticals Co., Ltd.